Community-Driven Antimicrobial Resistance Surveillance

By leveraging innovative data collection methods and citizen-related data integration, Antimicrobial Resistance Monitoring enables robust surveillance of AMR at the community level. Through the analysis of these data sets, the solution provides actionable insights to inform evidence-based policies and interventions. 

Dr. Emmanuel E. Etim, Associate Professor, Department of Chemical Sciences Federal University Wukari Nigeria and a Visiting Assistant Professor at the Indian Institute of Technology, Bombay, India.

1.27 million deaths globally are caused by bacterial AMR, making AMR an imminent threat to public health. Africa has a higher AMR/AMU (50.0%) than other continents (<43%). It is well-recognized that the veterinary, plant, and human sectors in LMICs abuse antibiotics. Antimicrobial susceptibility results are not routinely used in remote, low- and mid-income communities before treatment is started, except in specialized hospitals. This means that data from these facilities is rarely useful for informed, empirical treatment elsewhere. Antimicrobial Resistance Monitoring: Community-driven antimicrobial Resistance Surveillance addresses the specific problem of limited surveillance and understanding of antimicrobial resistance (AMR) in low- and middle-income communities. Currently, there is a significant gap in data collection and analysis at the community level, hindering efforts to effectively monitor and combat AMR. Antimicrobial Resistance Monitoring: Community-Driven Antimicrobial Resistance Surveillance seeks to bridge this gap by providing innovative solutions for data collection, integration, and analysis, thereby enabling communities to better understand the prevalence, drivers, and dynamics of AMR. By empowering communities with actionable insights, Antimicrobial Resistance Monitoring: Community-Driven Antimicrobial Resistance Surveillance aims to mitigate the spread of antimicrobial resistance and improve public health outcomes.

Antimicrobial resistance. (2023, November 21). https://www.who.int/news-room/...

The solution serves low- and middle-income communities facing challenges related to antimicrobial resistance (AMR). Specifically, it addresses the needs of:

Community Health Workers and Healthcare Providers: Providing them with tools and platforms for data collection and analysis, will help community health workers to monitor and respond to AMR effectively. The solution will equip healthcare providers with actionable insights derived from surveillance data, enabling them to make informed treatment decisions and promote antimicrobial stewardship.

Residents: By bridging the information and communication gaps between authorities and rural communities, students will also be instrumental in addressing the needs and concerns of the local community about AMR/AMU. The strategy places a strong emphasis on the value of educating the public about AMR and AMU while also establishing a community-level surveillance capacity that can be sustained. One essential element of this strategy is empowering students via education and community-based AMR/AMU activities. Antimicrobial Resistance Monitoring enhances awareness and understanding of AMR among community members, fostering engagement and participation in efforts to address this critical public health issue.

Policy Makers: By synthesizing community-level data on AMR, Antimicrobial Resistance Monitoring supports policy makers in developing evidence-based policies and interventions to combat AMR and protect public health.

Improved Public Health: By enhancing surveillance and understanding of AMR at the community level, the Community Antimicrobial Resistance monitoring system contributes to better public health outcomes by enabling timely detection and response to emerging threats of drug-resistant infections.

Sustainable Healthcare Systems: By strengthening community-based surveillance and intervention strategies, The Community Antimicrobial Resistance monitoring system supports the sustainability of healthcare systems in low- and middle-income countries, reducing the burden of AMR-related morbidity and mortality and improving healthcare access and quality for vulnerable populations.

One Health Approach: The Community Antimicrobial Resistance monitoring system facilitates the integration of human, animal, and environmental health data, fostering a One Health approach to AMR surveillance and mitigation efforts. By addressing the interconnectedness of these domains, the solution promotes holistic and sustainable solutions to combat antimicrobial resistance.

Capacity Building and Empowerment: The Community Antimicrobial Resistance monitoring system empowers local communities, healthcare workers, and policymakers by providing them with the tools, knowledge, and resources to actively participate in AMR surveillance and mitigation efforts. This capacity-building approach promotes local ownership and sustainability of interventions, leading to long-term improvements in public health outcomes.

The solution will improve healthcare outcomes by enabling early detection of antimicrobial resistance patterns and trends, healthcare providers can adjust treatment strategies, leading to improved patient outcomes and reduced morbidity and mortality rates. Also, the solution will empower communities. Community health workers and local stakeholders will be equipped with the tools and knowledge to actively participate in antimicrobial resistance surveillance and intervention efforts, fostering a sense of ownership and empowerment within communities.

 Furthermore, Addressing AMR through Community-driven solutions will yield significant economic benefits for communities and societies. By reducing the burden of drug-resistant infections, the solution will lower healthcare costs associated with prolonged illness, hospitalization, and treatment failures. Moreover, by preserving the efficacy of existing antibiotics and reducing the need for costly second-line treatments, Community-driven solutions can contribute to long-term savings in healthcare expenditures and productivity losses. Studies have shown that investments in AMR surveillance and control programs yield positive returns on investment through healthcare cost savings and economic gains. Lastly, the solution will facilitate the integration of human, animal, and environmental health data, promoting a holistic One Health approach to antimicrobial resistance surveillance and mitigation efforts, thereby benefiting both human and animal populations and the environment.

Over the next one year, we will focus on scaling our impact by conducting pilot deployments of antimicrobial resistance surveillance in low- and middle-income communities to validate its effectiveness, usability, and scalability in real-world settings. And also engage with key stakeholders, including community members, healthcare providers, policymakers, and local organizations, to gather feedback, build partnerships, and garner support for scaling up the solution. We will provide training and capacity-building initiatives for community health workers, healthcare providers, and policymakers to ensure effective implementation and sustainable use of antimicrobial resistance surveillance.

Over the next three years, we will further scale our impact by:

Scaling up antimicrobial resistance surveillance to additional communities and regions in Nigeria, leveraging insights and best practices from pilot deployments to replicate successful implementation models and reach a broader population. Integrate antimicrobial resistance surveillance into existing healthcare systems and infrastructure, including electronic health records and surveillance networks, to enhance its interoperability and sustainability.

Also, advocating for policy changes and investments in antimicrobial resistance surveillance and intervention efforts at the national and international levels, based on evidence generated by antimicrobial resistance surveillance. And Strengthening partnerships with governments, international organizations, academic institutions, and civil society organizations.

For the healthcare outcomes, we will measure the success through a reduction in the prevalence of antimicrobial-resistant infections, a decrease in morbidity and mortality rates associated with drug-resistant bacteria, and improved treatment outcomes and patient satisfaction.

For community empowerment, increased participation and engagement of community members in antimicrobial resistance surveillance and intervention activities and enhanced knowledge and skills of community health workers and local stakeholders in using antimicrobial resistance surveillance tools and resources are criteria that we will use to measure the success.

Nevertheless, the integration of human, animal, and environmental health data in antimicrobial resistance surveillance and intervention efforts and collaboration and coordination among relevant sectors and stakeholders to address antimicrobial resistance holistically will be checkmate in assessing the impact of the project.

Measurement methods may include quantitative data analysis (e.g., reduction in infection rates, antimicrobial consumption), qualitative assessments (e.g., community surveys, stakeholder interviews), and key performance indicators (e.g., percentage of healthcare facilities implementing antimicrobial stewardship programs). Regular monitoring and evaluation will be conducted to track progress against impact goals and make data-driven decisions for continuous improvement and adaptation of antimicrobial resistance monitoring.

Limited funding and resources have hindered the scaling up of antimicrobial resistance surveillance and the implementation of pilot projects. However, we are seeking financial support from Trinity Challenge. Additionally, we will prioritize resource allocation based on cost-effective strategies.

Furthermore, technical challenges such as data interoperability, connectivity issues, and software bugs may affect the functionality and usability of antimicrobial resistance surveillance.  We will invest in robust software development and quality assurance processes to identify and address technical issues proactively.

Regulatory barriers, bureaucratic hurdles, and policy constraints may delay the implementation and expansion of antimicrobial resistance surveillance initiatives. However, we will engage with policymakers, regulatory authorities, and advocacy groups to advocate for supportive policies, regulations, and standards that facilitate the deployment of antimicrobial resistance surveillance. 

The Trinity Challenge presents a unique opportunity to leverage our solution to address one of the most pressing global health challenges of our time: antimicrobial resistance (AMR). The Trinity Challenge offers a platform for funding opportunities to tackle complex health threats like AMR.

Being part of The Trinity Challenge raises the visibility and recognition of our solution on a global stage. This will help attract partners, collaborators, and investors, as well as amplify our impact and influence in the fight against AMR.

We are open to partnering with a diverse range of organizations that share our commitment to combating antimicrobial resistance (AMR) and have complementary expertise, resources, and networks to support the implementation and scale-up of our solution. We would collaborate with research/academic institutions, NGOs, pharmaceutical companies, private sectors, and government agencies.

Our preferred modes of partnership include joint implementation projects, co-funding initiatives, knowledge exchange and capacity-building activities, policy advocacy campaigns, and technology co-development efforts. We believe that by leveraging the expertise, resources, and networks of our partner organizations, we can amplify the impact of our solution and contribute to global efforts to combat antimicrobial resistance.